Abstract Number: 0534 • ACR Convergence 2024
Patient Reported Outcomes and Disease Activity from a Phase 1 Double-Blind Randomized Clinical Trial of Allogeneic Mesenchymal Stem Cells in Early Rheumatoid Arthritis
Background/Purpose: Mesenchymal stem (stromal) cells (MSCs) constitute an emerging therapeutic strategy for several human diseases. Small non-randomized studies have shown that MSCs may be a…Abstract Number: 0563 • ACR Convergence 2024
Clinical Features of Patients with SpA, with or Without IBD: Results from the METEOR Cohort
Background/Purpose: To investigate clinical features of SpA patients with and without IBD, identifying the patient group that would benefit from initiating therapy with efficacy in…Abstract Number: 0554 • ACR Convergence 2024
Different Prevalence of Intestinal Inflammation in Radiographic and Non-radiographic Axial Spondyloarthritis. Data from EISER Study
Background/Purpose: Axial spondyloarthritis (AxSpA) encompasses both non-radiographic axial spondyloarthritis (nr-AxSpA) and radiographic axial spondyloarthritis (r-AxSpA), also known as ankylosing spondylitis (AS). Although nr-AxSpA is often…Abstract Number: 0547 • ACR Convergence 2024
EspANDE Project: Improvement of Primary Care-Rheumatology Coordination in Spondyloarthritis in a Health Area in Northern Spain
Background/Purpose: Spondyloarthritis (SpA) constitutes a diverse set of inflammatory rheumatic diseases with a prevalence of 1.9% in the general population. Diagnostic delay, identified as a…Abstract Number: 0558 • ACR Convergence 2024
Patient Diagnostic Journey and Time to Diagnosis in Axial Spondyloarthritis: A Retrospective Cohort Study Using US Claims Data
Background/Purpose: The journey to axial spondyloarthritis (axSpA) diagnosis is often prolonged and challenging, resulting in poor clinical, psychological, social, and economic outcomes.1 Understanding the factors…Abstract Number: 0557 • ACR Convergence 2024
What Factors Are Associated with Pain Intensity in Axial Spondyloarthritis? Results from the International Map of Axial Spondyloarthritis (IMAS)
Background/Purpose: Severe pain in patients with axial spondyloarthritis (axSpA) can cause deterioration in their physical and mental health. The aim is to investigate factors associated…Abstract Number: 0550 • ACR Convergence 2024
Is the Diagnostic Delay Getting Shorter with Time for Patients with Spondyloarthritis? Data from the International ASAS-PerSpA Study
Background/Purpose: Although diagnostic tools and management of spondyloarthritis (SpA) have recently improved, data on their impact on diagnostic delay (DD) are still conflicting. In this…Abstract Number: 0542 • ACR Convergence 2024
Impact of Peripheral Arthritis on Disease Activity Outcomes in Patients with Axial Spondyloarthritis, Peripheral Spondyloarthritis and Psoriatic Arthritis. Data from the ASAS-PerSpA Study
Background/Purpose: Patients with spondyloarthritis (SpA) can present with several phenotypes (i.e., axial SpA (axSpA), peripheral SpA (pSpA) and Psoriatic Arthritis (PsA)) and peripheral arthritis can…Abstract Number: 0504 • ACR Convergence 2024
Janus Kinase Inhibitors Persist Longer Than Biologics in Rheumatoid Arthritis: Retrospective Analysis of Real-world Outpatient Data from the German Rhadar Database
Background/Purpose: Numerous biologic and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) have been approved for treating rheumatoid arthritis (RA), including Janus kinase inhibitors (JAKi), rituximab, abatacept,…Abstract Number: 0503 • ACR Convergence 2024
Use of Janus Kinase Inhibitors Before and After European Medicines Agency Safety Recommendations
Background/Purpose: Safety recommendations for Janus kinase inhibitors (JAKi) issued by the European Medical Agency (EMA) in 2023 could potentially influence prescription patterns for drugs used…Abstract Number: 0575 • ACR Convergence 2024
Combined Testing of anti-CD74 IgA and Anti-UH-axSpA Antibodies Increases the Diagnostic Potential for axSpA
Background/Purpose: Diagnosis of axial spondyloarthritis (axSpA) is challenging and a specific laboratory diagnostic test is lacking. Previously, we identified novel immunoglobulin G (IgG) and IgA…Abstract Number: 0394 • ACR Convergence 2024
Unveiling Major Challenges and Unmet Needs in the Therapeutic Approach to Systemic Juvenile Idiopathic Arthritis: The Patient Perspective
Background/Purpose: Despite continuous improvements in the therapeutic options for children with systemic juvenile idiopathic arthritis (sJIA), access to medications significantly differs among centres and countries.…Abstract Number: 0549 • ACR Convergence 2024
Global Distribution and Determinants of Diagnostic Delay Across Diverse Spondyloarthritis Entities: Data from the International ASAS-Perspa Study
Background/Purpose: Diagnostic delay (DD) in spondyloarthritis (SpA) is well documented, but most of the available data are reported in patients with axial SpA (axSpA). In…Abstract Number: 0537 • ACR Convergence 2024
Evaluating the Usage of Janus Kinase Inhibitors in Rheumatology and Its Impact on Cardiovascular Risk
Background/Purpose: Janus kinase (JAK) inhibitors have been widely used in treatingrheumatological conditions like rheumatoid arthritis and psoriatic arthritis. Despite theirefficacy, there are concerns regarding major…Abstract Number: 0411 • ACR Convergence 2024
Axial Radiographic Structural Damage in Enthesitis-Related Arthritis in Children and Young Adult Patients
Background/Purpose: Enthesitis-related arthritis (ERA), a distinct subtype of juvenile idiopathic arthritis (JIA) related to HLA-B27 status and peripheral and axial involvement, presents with insidious onset…
- « Previous Page
- 1
- …
- 350
- 351
- 352
- 353
- 354
- …
- 2607
- Next Page »
